Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease

doi:10.4254/wjh.v17.i11.110698

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 11

This Article

(45)

(47)

(0)

(1)

(642)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Hepatol. Nov 27, 2025; 17(11): 110698
Published online Nov 27, 2025. doi: 10.4254/wjh.v17.i11.110698

Table 2 Non-invasive fibrosis testing, n (%)

Cytokeratin 18 fragment (high: > 260 U/L)		Normal	High	P value	Odds ratio/95%CI
Steatotic liver disease	Metabolic dysfunction and alcohol-related liver disease	35 (36.5)	8 (27.6)	0.37810	1
Steatotic liver disease	Metabolic dysfunction-associated steatotic liver disease	61 (63.5)	21 (72.4)	0.37810	1.51/0.73-3.13
Sex	Woman	53 (55.2)	14 (48.3)	0.51180	1
Sex	Man	43 (44.8)	15 (51.7)	0.51180	1.32/0.58-3.04
Age	n	96	29	0.20098	0.98/0.94-1.01
	Median	63.0	59.0
	Q1 (25%)	56.5	48.5
	Q3 (75%)	70.0	69.8
Total bilirubin (normal range 0.3-1.2 mg/dL)	n	96	29	0.70006	1.48/0.59-3.71
	Median	0.80	0.80
	Q1 (25%)	0.60	0.60
	Q3 (75%)	1.00	1.08
Total protein (6.7-8.3 g/dL)	n	96	29	0.00357	4.83/1.65-14.02
	Median	7.40	7.60
	Q1 (25%)	7.05	7.40
	Q3 (75%)	7.60	7.83
Albumin (3.8-5.2 g/dL)	n	96	29	0.59102	1.55/0.53-4.53
	Median	4.30	4.30
	Q1 (25%)	4.00	4.08
	Q3 (75%)	4.50	4.60
PT (70%-130%)	n	96	29	0.31843	0.99/0.97-1.01
	Median	98.10	92.00
	Q1 (25%)	85.80	83.10
	Q3 (75%)	107.70	102.78
PT international normalized ratio (0.9-1.1)	n	96	29	0.29846	2.70/0.07-105.6
	Median	1.010	1.040
	Q1 (25%)	0.970	0.988
	Q3 (75%)	1.075	1.085
Creatinine (M: 0.61-1.04 mg/dL and W: 0.47-0.79 mg/dL)	n	96	29	0.93705	1.32/0.20-8.59
	Median	0.730	0.750
	Q1 (25%)	0.650	0.648
	Q3 (75%)	0.900	0.873
Body mass index	n	96	29	0.07636	1.06/0.98-1.15
	Median	25.01	26.63
	Q1 (25%)	22.41	23.32
	Q3 (75%)	27.61	30.20
Platelet count (M: [13.1-26.2] × 10⁴/μL and W: [13-36.9] × 10⁴/μL)	n	96	29	0.82183	1.00/0.94-1.06
	Median	18.75	16.80
	Q1 (25%)	15.35	15.50
	Q3 (75%)	21.90	24.03
AST (10-40 U/L)	n	96	29	< 0.00001	1.06/1.03-1.08
	Median	30.0	66.0
	Q1 (25%)	23.0	52.5
	Q3 (75%)	42.5	105.5
ALT (5-40 U/L)	n	96	29	< 0.00001	1.04/1.02-1.06
	Median	29.5	80.0
	Q1 (25%)	20.0	51.3
	Q3 (75%)	51.0	123.5
AST/ALT	n	96	29	0.04739	0.54/0.21-1.39
	Median	1.086	0.837
	Q1 (25%)	0.798	0.651
	Q3 (75%)	1.370	1.165
Alkaline phosphatase (38-113 U/L)	n	96	29	0.81045	1.00/0.99-1.02
	Median	81.5	85.0
	Q1 (25%)	65.5	63.3
	Q3 (75%)	103.5	104.3
γ-glutamyl transpeptidase (M: < 70 U/L and W: < 30 U/L)	n	96	29	0.00269	1.00/1-1.01
	Median	50.5	89.0
	Q1 (25%)	27.0	55.8
	Q3 (75%)	108.0	162.3
Ferritin (M: 39.4-340 ng/mL and W: 3.6-114 ng/mL)	n	85	25	0.00004	1.00/1.00-1.01
	Median	171.2	398.5
	Q1 (25%)	106.9	248.8
	Q3 (75%)	300.3	701.3
IgG (870-1700 mg/dL)	n	76	24	0.42663	1.00/1.00-1.00
	Median	1285.5	1327.5
	Q1 (25%)	1125.0	1132.0
	Q3 (75%)	1433.5	1582.0
IgM (M: 33-190 mg/dL and W: 46-260 mg/dL)	n	66	22	0.54697	1.00/1.00-1.01
	Median	86.5	90.5
	Q1 (25%)	56.0	58.0
	Q3 (75%)	123.0	134.0
IgA (110-410 mg/dL)	n	69	19	0.18399	1.00/1.00-1.01
	Median	251.0	322.0
	Q1 (25%)	195.5	201.0
	Q3 (75%)	315.8	430.3
Ammonia (30-80 μg/dL)	n	94	29	0.06502	0.98/0.95-1.01
	Median	40.0	37.0
	Q1 (25%)	35.0	29.8
	Q3 (75%)	51.0	43.0
TG (50-149 mg/dL)	n	96	29	0.00117	1.00/1.00-1.01
	Median	100.5	160.0
	Q1 (25%)	70.5	114.8
	Q3 (75%)	165.5	234.3
LDL (70-139 mg/dL)	n	93	28	0.64258	1.00/0.99-1.02
	Median	109.0	113.0
	Q1 (25%)	91.3	92.0
	Q3 (75%)	139.0	141.0
HDL (M: 40-80 mg/dL and W: 40-90 mg/dL)	n	96	29	0.00340	0.95/0.92-0.99
	Median	63.0	54.0
	Q1 (25%)	52.0	42.8
	Q3 (75%)	74.5	61.8
TG/HDL	n	96	29	0.00041	1.28/1.06-1.54
	Median	1.654	3.260
	Q1 (25%)	1.109	1.764
	Q3 (75%)	3.014	5.545
Small dense LDL (> 35 mg/dL)	n	71	23	0.15677	1.01/0.99-1.03
	Median	35.4	39.6
	Q1 (25%)	20.9	29.8
	Q3 (75%)	48.5	52.0
Hemoglobin A1c (4.8%-6%)	n	93	28	0.02446	1.27/0.88-1.84
	Median	5.8	6.1
	Q1 (25%)	5.5	5.8
	Q3 (75%)	6.2	6.6

The odds ratio and 95% confidence interval were calculated using univariate logistic analysis. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; HDL: High-density lipoprotein; Ig: Immunoglobulin; LDL: Low-density lipoprotein; M: Men; PT: Prothrombin time; Q1: Quartile 1 (25%); Q3: Quartile 3 (75%); TG: Triglyceride; W: Women.

Full Size Table

Citation: Ichikawa T, Miuma S, Yamashima M, Yamamichi S, Koike M, Nakano Y, Yajima H, Miyazaki O, Ikeda T, Okamura T, Komatsu N, Yoshino M, Miyaaki H. Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease. World J Hepatol 2025; 17(11): 110698
URL: https://www.wjgnet.com/1948-5182/full/v17/i11/110698.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i11.110698

Ichikawa T, Miuma S, Yamashima M, Yamamichi S, Koike M, Nakano Y, Yajima H, Miyazaki O, Ikeda T, Okamura T, Komatsu N, Yoshino M, Miyaaki H. Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease. World J Hepatol 2025; 17(11): 110698 [PMID: 41368122 DOI: 10.4254/wjh.v17.i11.110698]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.